• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Progyny, Inc. Announces First Quarter 2025 Results

    5/8/25 4:14:54 PM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care
    Get the next $PGNY alert in real time by email

    Reports Record Revenue of $324.0 Million, Reflecting 16.5% Growth

    Raises Full Year Guidance Due to Strong Start to the Year

    Early Selling Season Activity Reflects Ongoing Demand in Women's Health and Family Building Solutions

    NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY) ("Progyny" or the "Company"), a global leader in women's health and family building solutions, today announced its financial results for the three-month period ended March 31, 2025 ("the first quarter of 2025") as compared to the three-month period ended March 31, 2024 ("the first quarter of 2024" or "the prior year period").

    "We're pleased with the strong start to the year, highlighted by both our solid financial results as well as the progress made with our investments to expand the platform and extend our leading position as the solution of choice in women's health and family building," said Pete Anevski, Chief Executive Officer of Progyny.

    "As HR leaders begin to consider their benefits strategies for next year, we continue to see that women's health and family building remain a priority for all types of employers," continued Anevski. "Although it's early in the selling season - and a number of things can still impact how the year unfolds, including the ongoing macro economic uncertainty - with the visibility we have into current overall sales activity, we're off to a good start and we believe we have multiple pathways to meet our sales goals for the year."

    "The first quarter results reflect double-digit revenue growth, increased gross margin, and significant cash flow. In addition, member engagement continues to be consistent with the historical range, reinforcing - once again - that the desire to pursue family building is fundamental to our members," said Mark Livingston, Progyny's Chief Financial Officer.

    First Quarter 2025 Highlights:

    (unaudited; in thousands, except per share amounts)1Q 2025 1Q 2024
    Revenue$324,038  $278,078 
        
    Gross Profit$75,795  $62,406 
    Gross Margin 23.4%  22.4%
    Net Income$15,059  $16,898 
        
    Net Income per Diluted Share1 $0.17  $0.17 
        
    Adjusted Earnings per Diluted Share2$0.48  $0.39 
        
    Adjusted EBITDA2$57,790  $50,291 
    Adjusted EBITDA Margin2 17.8%  18.1%
            
    1. Net income per diluted share reflects weighted-average shares outstanding as adjusted for potential dilutive securities, including options, restricted stock units, warrants to purchase common stock, and shares issuable under the employee stock purchase plan.
    2. Adjusted Earnings per Diluted Share, Adjusted EBITDA, and Adjusted EBITDA margin are financial measures that are not required by, or presented in accordance with, U.S. generally accepted accounting principles ("GAAP"). Please see Annex A of this press release for a reconciliation of Adjusted Earnings per Diluted Share to earnings per share, and Adjusted EBITDA to net income, the most directly comparable financial measures stated in accordance with GAAP for each of the periods presented. We calculate Adjusted Earnings per Diluted Share as net income per diluted share excluding the impact of stock-based compensation, adjusted for the impact of taxes. We calculate Adjusted EBITDA margin as Adjusted EBITDA divided by revenue.

    Financial Highlights

    Revenue was $324.0 million, a 16.5% increase as compared to the $278.1 million reported in the first quarter of 2024, primarily as a result of the increase in our number of clients and covered lives. As previously disclosed, a large client did not renew its services agreement for 2025, though it provided for an extended transition period over the first half of 2025 for members meeting certain criteria. Excluding the $31.3 million and $31.5 million of revenue from this client in the first quarters of 2025 and 2024, respectively, revenue increased 19%.

    • Fertility benefit services revenue was $206.4 million, a 22% increase from the $169.8 million reported in the first quarter of 2024.
    • Pharmacy benefit services revenue was $117.6 million, a 9% increase as compared to the $108.3 million reported in the first quarter of 2024.

    Gross profit was $75.8 million, an increase of 21% from the $62.4 million reported in the first quarter of 2024, primarily due to the higher revenue. Gross margin was 23.4%, as compared to the 22.4% reported in the prior year period.

    Net income was $15.1 million, or $0.17 income per diluted share, as compared to the $16.9 million, or $0.17 income per diluted share, reported in the first quarter of 2024. The lower net income was due primarily to a higher provision for income taxes driven by the discrete tax impacts of equity compensation, which more than offset the higher operating profit.

    Adjusted EBITDA was $57.8 million, an increase of 15% as compared to the $50.3 million reported in the first quarter of 2024, as the higher gross profit was partially offset by increased investments to expand the platform and integrate recent acquisitions. Adjusted EBITDA margin was 17.8% as compared to the 18.1% Adjusted EBITDA margin in the first quarter of 2024. Please refer to Annex A for a reconciliation of Adjusted EBITDA to net income.

    Cash Flow

    Net cash provided by operating activities in the first quarter of 2025 was $49.8 million, as compared to net cash provided by operating activities of $25.7 million in the prior year period. The higher cash flow as compared to the prior year period was due to higher profitability as well as the timing impact of certain working capital items in both periods.

    Balance Sheet and Financial Position

    As of March 31, 2025, the Company had total working capital of approximately $330.6 million and no debt. This included cash and cash equivalents and marketable securities of $256.1 million, an increase of $28.2 million from the balances as of December 31, 2024.

    Key Metrics

    The Company had 532 fertility and family building clients as of March 31, 2025, as compared to 451 clients as of March 31, 2024.

     Three Months Ended

    March 31,
     2025 2024
    ART Cycles*16,160  14,802 
    Utilization – All Members**0.54% 0.53%
    Utilization – Female Only**0.46% 0.46%
    Average Members***6,695,000  6,350,000 
          

    * Represents the number of ART cycles performed, including IVF with a fresh embryo transfer, IVF freeze all cycles/embryo banking, frozen embryo transfers, and egg freezing. Includes ART cycles performed in 2025 under the extended transition of care agreement with the large client who did not renew its services agreement.

    ** Represents the member utilization rate for all fertility and family building services, including, but not limited to, ART cycles, initial consultations, IUIs, and genetic testing. The utilization rate for all members includes all unique members (female and male) who utilize the benefit during that period, while the utilization rate for female only includes only unique females who utilize the benefit during that period. For purposes of calculating utilization rates in any given period, the results reflect the number of unique members utilizing the benefit for that period. Individual periods cannot be combined as member treatments may span multiple periods. Utilization for 2025 excludes activity under the extended transition of care agreement with the large client who did not renew its services agreement, as only members meeting certain criteria were eligible to use the benefit.

    ***Includes approximately 300,000 members from a single client who are not reflected in utilization as a result of the client's chosen benefit design. 2025 excludes the limited number of members who were eligible to use the benefit under the extended transition of care agreement with the large client who did not renew its services agreement.

    Financial Outlook

    "As the second quarter begins, member engagement is pacing consistent with the first quarter. Nonetheless, given the variability we experienced in 2024 and the ongoing uncertainty in the macro environment, the guidance we're issuing today reflects a range of engagement and activity in 2025," said Mr. Anevski. "The guidance also reflects the impact of our previously announced investments in member experience and acquisition integration - which we expect will ramp in the second quarter and continue over the balance of the year - as well as the wind down in the transition of care agreement with the large client, and no contribution over the second half of the year."

    The Company is providing the following financial guidance for the full year period ending December 31, 2025 and the three-month period ending June 30, 2025:

    • Full Year 2025 Outlook:
      • Revenue is now projected to be $1.185 billion to $1.235 billion, reflecting growth of 1.5% to 5.8%, including $44.0 million to $46.0 million of revenue from the transition of care agreement with the large client
      • Net income is projected to be $42.4 million to $51.8 million, or $0.46 to $0.56 per diluted share, on the basis of approximately 92 million assumed weighted-average fully diluted-shares outstanding
      • Adjusted EBITDA1 is projected to be $190.0 million to $203.0 million
      • Adjusted earnings per diluted share1 is projected to be $1.54 to $1.64



    • Second Quarter of 2025 Outlook:



      • Revenue is projected to be $310.0 million to $325.0 million, reflecting growth of 1.9% to 6.9%, including $12.7 million to $14.7 million of revenue from the transition of care agreement with the large client
      • Net income is projected to be $11.5 million to $14.5 million, or $0.13 to $0.16 per diluted share, on the basis of approximately 91 million assumed weighted-average fully diluted-shares outstanding
      • Adjusted EBITDA1 is projected to be $49.0 million to $53.0 million
      • Adjusted earnings per diluted share1 is projected to be $0.40 to $0.43

    1. Adjusted EBITDA and Adjusted earnings per diluted share are financial measures that are not required by, or presented in accordance with, GAAP. Please see Annex A of this press release for a reconciliation of forward-looking Adjusted EBITDA to forward-looking net income and Adjusted net income to net income, the most directly comparable financial measures stated in accordance with GAAP, for the period presented.

    Conference Call Information

    Progyny will host a conference call at 4:45 P.M. Eastern Time (1:45 P.M. Pacific Time) today, May 8, 2025, to discuss its financial results. Interested participants from the United States may join by calling 1.866.825.7331 and using conference ID 265484. Participants from international locations may join by calling 1.973.413.6106 and using the same conference ID. A replay of the call will be available until May 15, 2025 at 5:00 P.M. Eastern Time by dialing 1.800.332.6854 (U.S. participants) or 1.973.528.0005 (international) and entering passcode 265484. A live audio webcast of the call and subsequent replay will also be available through the Events & Presentations section of the Company's Investor Relations website at investors.progyny.com.

    About Progyny

    Progyny (NASDAQ:PGNY) is a global leader in women's health and family building solutions, trusted by the nation's leading employers, health plans and benefit purchasers. We envision a world where everyone can realize their dreams of family and ideal health. Our outcomes prove that comprehensive, inclusive and intentionally designed solutions simultaneously benefit employers, patients, and physicians.

    Our benefits solution empowers patients with concierge support, coaching, education, and digital tools; provides access to a premier network of fertility and women's health specialists who use the latest science and technologies; drives optimal clinical outcomes; and reduces healthcare costs.

    Headquartered in New York City, Progyny has been recognized for its leadership and growth as a TIME100 Most Influential Company, CNBC Disruptor 50, Modern Healthcare's Best Places to Work in Healthcare, Forbes' Best Employers, Financial Times Fastest Growing Companies, INC. 5000, INC. Power Partners and Crain's Fast 50 for NYC. For more information, visit www.progyny.com.

    Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this press release other than statements of historical fact, including, without limitation, statements regarding our financial outlook for the second quarter and full year 2025, including the impact of our sales season and client launches; our anticipated number of clients and covered lives for 2025; our expected utilization rates and mix; the demand for our solutions; our expectations for our selling season for 2026 launches; our positioning to successfully manage economic uncertainty on our business; the timing of client decisions; our ability to retain existing clients and acquire new clients; and our business strategy, plans, goals and expectations concerning our market position, future operations, and other financial and operating information. The words "anticipates," "assumes," "believe," "contemplate," "continues, " "could," "estimates," "expects," "future," "intends," "may," "plans," "predict," "potential," "project," "seeks," "should," "target," "will," and the negative of these or similar expressions and phrases are intended to identify forward-looking statements, though not all forward-looking statements use these words or expressions.

    Forward-looking statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks include, without limitation, failure to meet our publicly announced guidance or other expectations about our business; competition in the market in which we operate; our history of operating losses and ability to sustain profitability; unfavorable conditions in our industry or the United States economy; our limited operating history and the difficulty in predicting our future results of operations; our ability to attract and retain clients and increase the adoption of services within our client base; the loss of any of our largest client accounts; changes in the technology industry; changes or developments in the health insurance market; negative publicity in the health benefits industry; lags, failures or security breaches in our computer systems or those of our vendors; a significant change in the utilization of our solutions; our ability to offer high-quality support; positive references from our existing clients; our ability to develop and expand our marketing and sales capabilities; the rate of growth of our future revenue; the accuracy of the estimates and assumptions we use to determine the size of target markets; our ability to successfully manage our growth; reductions in employee benefits spending; seasonal fluctuations in our sales; the adoption of new solutions and services by our clients or members; our ability to innovate and develop new offerings; our ability to adapt and respond to the changing medical landscape, regulations, and client needs, requirements or preferences; our ability to maintain and enhance our brand; our ability to attract and retain members of our management team, key employees, or other qualified personnel; risks related to any litigation against us; our ability to maintain our Center of Excellence network of healthcare providers; our strategic relationships with and monitoring of third parties; our ability to maintain our pharmacy distribution network if there is a disruption to our network or its associated supply chains; our relationship with key pharmacy program partners or any decline in rebates provided by them; our ability to maintain our relationships with benefits consultants; exposure to credit risk from our members; risks related to government regulation; risks related to our business with government entities; our ability to protect our intellectual property rights; risks related to acquisitions, strategic investments, or partnerships; federal tax reform and changes to our effective tax rate; the imposition of state and local state taxes; our ability to utilize a portion of our net operating loss or research tax credit carryforwards; our ability to develop or maintain effective internal control over financial reporting; and our ability to adapt and respond to the changing SEC or stakeholder expectations regarding environmental, social and governance practices. For a detailed discussion of these and other risk factors, please refer to our filings with the Securities and Exchange Commission (the "SEC"), including in the section entitled "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and subsequent reports that we file with the SEC, which are available at http://investors.progyny.com and on the SEC's website at https://www.sec.gov.

    Forward-looking statements represent our management's beliefs and assumptions only as of the date of this press release. Our actual future results could differ materially from what we expect. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons.

    Non-GAAP Financial Measures

    In addition to disclosing financial measures prepared in accordance with U.S. generally accepted accounting principles ("GAAP"), this press release and the accompanying tables include the non-GAAP financial measures Adjusted EBITDA, Adjusted EBITDA margin, Adjusted EBITDA margin on incremental revenue and Adjusted earnings per diluted share.

    Adjusted EBITDA, Adjusted EBITDA margin, Adjusted EBITDA margin on incremental revenue and Adjusted earnings per diluted share are supplemental financial measures that are not required by, or presented in accordance with, GAAP. We believe that these non-GAAP measures, when taken together with our GAAP financial results, provide meaningful supplemental information regarding our operating performance and facilitates internal comparisons of our historical operating performance on a more consistent basis by excluding certain items that may not be indicative of our business, results of operations or outlook. In particular, we believe that the use of Adjusted EBITDA, Adjusted EBITDA margin, Adjusted EBITDA margin on incremental revenue and Adjusted earnings per diluted share are helpful to our investors as they are measures used by management in assessing the health of our business, determining incentive compensation, evaluating our operating performance, and for internal planning and forecasting purposes.

    Adjusted EBITDA, Adjusted EBITDA margin, Adjusted EBITDA margin on incremental revenue and Adjusted earnings per diluted share are presented for supplemental informational purposes only, have limitations as analytical tools and should not be considered in isolation or as a substitute for financial information presented in accordance with GAAP. Some of the limitations of Adjusted EBITDA, Adjusted EBITDA margin, Adjusted EBITDA margin on incremental revenue and Adjusted earnings per diluted share include: (1) it does not properly reflect capital commitments to be paid in the future; (2) although depreciation and amortization are non-cash charges, the underlying assets may need to be replaced and Adjusted EBITDA does not reflect these capital expenditures; (3) it does not consider the impact of stock-based compensation expense; (4) it does not reflect other non-operating income and expenses, including interest and other income, net; and (5) it does not reflect tax payments that may represent a reduction in cash available to us. In addition, our non-GAAP measures may not be comparable to similarly titled measures of other companies because they may not calculate such measures in the same manner as we calculate these measures, limiting their usefulness as comparative measures. Because of these limitations, when evaluating our performance, you should consider Adjusted EBITDA, Adjusted EBITDA margin, Adjusted EBITDA margin on incremental revenue and Adjusted earnings per diluted share alongside other financial performance measures, including our net income, gross margin, and our other GAAP results.

    We calculate Adjusted EBITDA as net income, adjusted to exclude depreciation and amortization; stock-based compensation expense; interest and other income, net; and provision for income taxes. We calculate Adjusted EBITDA margin as Adjusted EBITDA divided by revenue. We calculate Adjusted EBITDA margin on incremental revenue as incremental Adjusted EBITDA in 2025 divided by incremental revenue in 2025. We calculate Adjusted earnings per diluted share as net income per diluted share excluding the impact of stock-based compensation, adjusted for the associated impact of taxes. Please see Annex A: "Reconciliation of GAAP to Non-GAAP Financial Measures" elsewhere in this press release.

    For Further Information, Please Contact:

    Investors:Media:
    James HartAlexis Ford
    [email protected][email protected]



     
    PROGYNY, INC.

    Consolidated Balance Sheets

    (Unaudited)

    (in thousands, except share and per share amounts)
     
     March 31, December 31,
      2025  2024
    ASSETS   
    Current assets:   
    Cash and cash equivalents$109,239  $162,314 
    Marketable securities 146,884   65,640 
    Accounts receivable, net of $58,610 and $56,355 of allowance at March 31, 2025 and December 31, 2024, respectively 299,743   235,324 
    Prepaid expenses and other current assets 11,826   9,443 
    Total current assets 567,692   472,721 
    Property and equipment, net 15,740   12,383 
    Operating lease right-of-use assets 26,949   17,251 
    Goodwill 19,651   15,534 
    Intangible assets, net 6,753   1,303 
    Deferred tax assets 84,948   84,933 
    Other noncurrent assets 8,552   2,977 
    Total assets$730,285  $607,102 
    LIABILITIES AND STOCKHOLDERS' EQUITY    
    Current liabilities:   
    Accounts payable$145,713  $95,097 
    Accrued expenses and other current liabilities 91,415   73,530 
    Total current liabilities 237,128   168,627 
    Operating lease noncurrent liabilities 25,998   16,413 
    Total liabilities 263,126   185,040 
    Commitments and Contingencies   
    STOCKHOLDERS' EQUITY   
    Common stock, $0.0001 par value; 1,000,000,000 shares authorized; at March 31, 2025 and December 31, 2024, respectively; 98,052,017 and 97,692,891 shares issued; 85,669,824 and 85,310,698 outstanding at March 31, 2025 and December 31, 2024, respectively 9   9 
    Additional paid-in capital 611,563   581,596 
    Treasury stock, at cost, $0.0001 par value; 12,998,173 and 12,998,173 shares at March 31, 2025 and December 31, 2024, respectively (303,889)  (303,889)
    Accumulated earnings 159,366   144,307 
    Accumulated other comprehensive income 110   39 
    Total stockholders' equity  467,159   422,062 
    Total liabilities and stockholders' equity $730,285  $607,102 
        



     
    PROGYNY, INC.

    Consolidated Statements of Operations

    (Unaudited)

    (in thousands, except share and per share amounts)
     
     Three Months Ended

    March 31,
     2025 2024
    Revenue$324,038 $278,078
    Cost of services 248,243  215,672
    Gross profit 75,795  62,406
    Operating expenses:   
    Sales and marketing 17,786  15,454
    General and administrative 33,839  28,429
    Total operating expenses 51,625  43,883
    Income from operations 24,170  18,523
    Interest and other income, net 2,367  3,992
    Income before income taxes 26,537  22,515
    Provision for income taxes 11,478  5,617
    Net income$15,059 $16,898
    Net income per share:   
    Basic$0.18 $0.18
    Diluted$0.17 $0.17
    Weighted-average shares used in computing net income per share:   
    Basic 85,499,153  96,484,657
    Diluted 89,307,934  101,052,933



     
    PROGYNY, INC.

    Consolidated Statements of Cash Flows

    (Unaudited)

    (in thousands)
     
      Three Months Ended

    March 31,
      2025 2024
    OPERATING ACTIVITIES    
    Net income $15,059  $16,898 
    Adjustments to reconcile net income to net cash provided by operating activities:    
    Deferred tax expense  11   2,877 
    Non-cash interest income  —   (190)
    Depreciation and amortization  1,108   716 
    Loss on disposal of property and equipment  79   — 
    Stock-based compensation expense  32,512   31,052 
    Bad debt expense  5,659   4,772 
    Net accretion of discounts on marketable securities  1,106   (3,395)
    Foreign currency exchange rate loss  —   35 
    Changes in operating assets and liabilities:    
    Accounts receivable  (69,732)  (60,118)
    Prepaid expenses and other current assets  (2,383)  15,169 
    Accounts payable  49,618   4,790 
    Accrued expenses and other current liabilities  17,509   12,995 
    Other noncurrent assets and liabilities  (738)  131 
    Net cash provided by operating activities  49,808   25,732 
         
    INVESTING ACTIVITIES    
    Purchase of property and equipment, net  (2,843)  (850)
    Purchase of marketable securities  (145,809)  (110,806)
    Sale of marketable securities  63,382   131,000 
    Acquisition of business, net of cash acquired  (9,340)  — 
    Net cash (used in) provided by investing activities  (94,610)  19,344 
         
    FINANCING ACTIVITIES    
    Repurchase of common stock  —   (23,764)
    Proceeds from exercise of stock options  39   962 
    Payment of employee taxes related to equity awards  (3,583)  (4,959)
    Proceeds from contributions to employee stock purchase plan  256   350 
    Net cash used in financing activities  (3,288)  (27,411)
    Effect of exchange rate changes on cash, cash equivalents, and restricted cash  15   (2)
    Net (decrease) increase in cash, cash equivalents, and restricted cash  (48,075)  17,663 
    Cash, cash equivalents, and restricted cash, beginning of period  162,314   97,296 
    Cash, cash equivalents, and restricted cash, end of period $114,239  $114,959 
         
    Cash and cash equivalents  109,239   114,959 
    Restricted cash included within noncurrent assets  5,000   — 
    Total cash, cash equivalents, and restricted cash  114,239   114,959 
         
    SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION    
    Cash paid for income taxes, net of refunds received $400  $(362)
    SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES    
    Additions of property and equipment, net included in accounts payable and accrued expenses $1,246  $155 



     
    ANNEX A



    PROGYNY, INC.

    Reconciliation of GAAP to Non-GAAP Financial Measures

    -(unaudited)

    (in thousands, except share and per share amounts)
     

    Costs of Services, Gross Margin and Operating Expenses Excluding Stock-Based Compensation Calculation

    The following table provides a reconciliation of cost of services, gross profit, sales and marketing and general and administrative expenses to each of these measures excluding the impact of stock-based compensation expense for each of the periods presented:

      Three Months Ended
      March 31, 2025
         GAAP Stock-Based

    Compensation

    Expense
     Non-GAAP
           
    Cost of services $248,243  $(9,398) $238,845 
    Gross profit $75,795  $9,398  $85,193 
    Sales and marketing $17,786  $(7,875) $9,911 
    General and administrative $33,839  $(15,239) $18,600 
           
    Expressed as a Percentage of Revenue  
    Gross margin  23.4%  2.9%  26.3%
    Sales and marketing  5.5% (2.4)%  3.1%
    General and administrative  10.4% (4.7)%  5.7%
           
      Three Months Ended
      March 31, 2024
         GAAP Stock-Based

    Compensation

    Expense
     Non-GAAP
           
    Cost of services $215,672  $(9,033) $206,639 
    Gross profit $62,406  $9,033  $71,439 
    Sales and marketing $15,454  $(7,503) $7,951 
    General and administrative $28,429  $(14,516) $13,913 
           
    Expressed as a Percentage of Revenue  
    Gross margin  22.4%  3.2%  25.7%
    Sales and marketing  5.6% (2.7)%  2.9%
    General and administrative  10.2% (5.2)%  5.0%
                

    Note: percentages shown in the table may not cross foot due to rounding.



    Adjusted Earnings Per Diluted Share Calculation


    The following table provides a reconciliation of net income to Adjusted Earnings Per Diluted Share for each of the periods presented:

       
      Three Months Ended
      March 31, 2025
       
    Net Income $15,059 
    Add:  
    Stock-based compensation expense  32,512 
    Income tax effect of non-GAAP adjustment  (4,523)
    Adjusted Net income $43,048 
       
    Diluted Shares  89,307,934 
    Adjusted Earnings Per Diluted Share $0.48 
       
      Three Months Ended
      March 31, 2024
       
    Net Income $16,898 
    Add:  
    Stock-based compensation expense  31,052 
    Income tax effect of non-GAAP adjustment  (8,817)
    Adjusted Net income $39,133 
       
    Diluted Shares  101,052,933 
    Adjusted Earnings Per Diluted Share $0.39 
       

    Adjusted EBITDA and Adjusted EBITDA Margin on Incremental Revenue Calculation

    The following table provides a reconciliation of Net income to Adjusted EBITDA for each of the periods presented:

      Three Months Ended
      March 31,
      2025 2024
         
    Net income $15,059  $16,898 
    Add:    
    Depreciation and amortization  1,108   716 
    Stock‑based compensation expense  32,512   31,052 
    Interest and other income, net  (2,367)  (3,992)
    Provision for income taxes  11,478   5,617 
    Adjusted EBITDA $57,790  $50,291 
         
    Revenue $324,038  $278,078 
         
    Incremental revenue vs. 2024  45,960   
         
    Incremental Adjusted EBITDA vs. 2024  7,499   
         
           
    Incremental Adj EBITDA margin on incremental revenue  16.3%  
           

    Reconciliation of Non-GAAP Financial Guidance for the Three Months Ending June 30, 2025 and Year Ending December 31, 2025

      Three Months Ending

    June 30, 2025
     Year Ending

    December 31, 2025
      Low High Low High
             
    Revenue $310,000  $325,000  $1,185,000  $1,235,000 
    Net Income $11,500  $14,500  $42,400  $51,800 
    Add:        
    Depreciation and amortization  1,500   1,500   6,000   6,000 
    Stock-based compensation expense  32,500   32,500   127,000   127,000 
    Interest and other income, net  (2,000)  (2,000)  (9,700)  (9,700)
    Provision for income taxes  5,500   6,500   24,300   27,900 
    Adjusted EBITDA* $49,000  $53,000  $190,000  $203,000 



      Three Months Ending

    June 30, 2025
     Year Ending

    December 31, 2025
      Low High Low High
             
    Net Income $11,500  $14,500  $42,400  $51,800 
    Add:        
    Stock-based compensation  32,500   32,500   127,000   127,000 
    Income tax effect of non-GAAP adjustment  (8,000)  (8,000)  (28,000)  (28,000)
    Adjusted Net income* $36,000  $39,000  $141,400  $150,800 
             
    Diluted Shares  91,000,000   91,000,000   92,000,000   92,000,000 
    Adjusted Earnings Per Diluted Share $0.40  $0.43  $1.54  $1.64 
                     

    * All of the numbers in the tables above reflect our future outlook as of the date hereof.  Net income, Adjusted Net Income and Adjusted EBITDA ranges do not reflect any estimate for other potential activities and transactions, nor do they contemplate any discrete income tax items, including the income tax impact related to equity compensation activity.



    Assisted Reproductive Technology (ART) Cycles per Unique Female Utilizer

    The following tables provide historical trend and guidance assumptions for average members, female utilization rate, and ART Cycles per Unique Female Utilizer for the full year and quarterly periods presented:

              Guidance Assumptions For:
              Year Ending December 31, 2025
      Year Ending December 31, Low End as of  High End as of
      2021 2022 2023 2024 1 May 8, 20251 May 8, 20251
    Average Members  2,812,000   4,349,000   5,383,000   6,104,0001   6,450,0001,2  6,450,0001,2
                 
    Female Utilization Rate  1.07%  1.03%  1.09%  1.07% 1.02%2 1.04%2
                 
    Female Unique Utilizers  30,053   44,600   58,596   65,077   66,1002  67,4002
                 
    ART Cycles  28,413   42,598   58,013   61,114   61,800  64,500
                 
    ART Cycles per Unique Female Utilizer  0.95   0.96   0.99   0.94   0.89  0.91
                 
    Revenue ($ in millions) $500.6  $786.9  $1,088.6  $1,167.2  $1,185.0 $1,235.0
                           

    1 Calculations for 2024 and 2025 exclude approximately 300,000 members from a single client not reflected in female utilizers as a result of the client's chosen benefit design.

    2 Calculations exclude activity from a large client whose program discontinued for 2025, but who allowed for an extended period of transition of care for certain members.



    Quarterly ART Cycles per Unique Female Utilizer

      Three Months Ending Year Ending
      March 31, June 30, September 30, December 31, December 31,
    2022 0.50 0.55 0.56 0.58 0.96
               
    2023 0.51 0.55 0.56 0.58 0.99
               
    2024* 0.53 0.54 0.52 0.54 0.94
               
    2025: Low End of Guidance Range 0.51 0.50E     0.89E
               
    2025: High End of Guidance Range 0.51 0.52E     0.91E
               

    *Calculations for 2024 and 2025 exclude approximately 300,000 members from a single client not reflected in female utilizers as a result of the client's chosen benefit design.

    E indicates the estimated value assumed.



    Primary Logo

    Get the next $PGNY alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PGNY

    DatePrice TargetRatingAnalyst
    12/2/2024$17.00Overweight → Neutral
    Analyst
    11/13/2024$26.00 → $19.00Buy → Hold
    Truist
    9/19/2024Mkt Outperform → Mkt Perform
    JMP Securities
    8/7/2024$37.00 → $24.00Buy → Hold
    Canaccord Genuity
    8/7/2024$31.00 → $25.00Outperform → Market Perform
    Leerink Partners
    8/7/2024Buy → Neutral
    BTIG Research
    7/16/2024$36.00Mkt Outperform
    JMP Securities
    5/10/2024Overweight → Sector Weight
    KeyBanc Capital Markets
    More analyst ratings

    $PGNY
    SEC Filings

    See more
    • SEC Form 10-Q filed by Progyny Inc.

      10-Q - Progyny, Inc. (0001551306) (Filer)

      5/9/25 4:31:42 PM ET
      $PGNY
      Misc Health and Biotechnology Services
      Health Care
    • Progyny Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Progyny, Inc. (0001551306) (Filer)

      5/8/25 4:22:47 PM ET
      $PGNY
      Misc Health and Biotechnology Services
      Health Care
    • SEC Form SCHEDULE 13G filed by Progyny Inc.

      SCHEDULE 13G - Progyny, Inc. (0001551306) (Subject)

      4/29/25 3:52:52 PM ET
      $PGNY
      Misc Health and Biotechnology Services
      Health Care

    $PGNY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Operating Officer Cummings Melissa B was granted 41,667 shares (SEC Form 4)

      4 - Progyny, Inc. (0001551306) (Issuer)

      5/2/25 6:08:28 PM ET
      $PGNY
      Misc Health and Biotechnology Services
      Health Care
    • SEC Form 3 filed by new insider Cummings Melissa B

      3 - Progyny, Inc. (0001551306) (Issuer)

      5/2/25 6:01:18 PM ET
      $PGNY
      Misc Health and Biotechnology Services
      Health Care
    • New insider Clapp Geoffrey claimed ownership of 28,694 shares (SEC Form 3)

      3 - Progyny, Inc. (0001551306) (Issuer)

      5/2/25 6:00:23 PM ET
      $PGNY
      Misc Health and Biotechnology Services
      Health Care

    $PGNY
    Financials

    Live finance-specific insights

    See more
    • Progyny, Inc. Announces First Quarter 2025 Results

      Reports Record Revenue of $324.0 Million, Reflecting 16.5% GrowthRaises Full Year Guidance Due to Strong Start to the YearEarly Selling Season Activity Reflects Ongoing Demand in Women's Health and Family Building Solutions NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY) ("Progyny" or the "Company"), a global leader in women's health and family building solutions, today announced its financial results for the three-month period ended March 31, 2025 ("the first quarter of 2025") as compared to the three-month period ended March 31, 2024 ("the first quarter of 2024" or "the prior year period"). "We're pleased with the strong start to the year, highlighted by both our

      5/8/25 4:14:54 PM ET
      $PGNY
      Misc Health and Biotechnology Services
      Health Care
    • Progyny, Inc. Announces Details for Its First Quarter 2025 Results Report

      NEW YORK, April 24, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY), a global leader in women's health and family building, will report its financial results for the quarterly period ended March 31, 2025, after the close of the market on Thursday, May 8, 2025. The company will host a conference call at 4:45 p.m. Eastern Time (1:45 p.m. Pacific Time) and issue a press release regarding its financial results prior to the start of the call. Interested participants in the United States may access the conference call by dialing 1.866.825.7331 and using the passcode 265484. International participants may access the call by dialing 1.973.413.6106 and using the same passcode. An audio repl

      4/24/25 2:49:33 PM ET
      $PGNY
      Misc Health and Biotechnology Services
      Health Care
    • Progyny, Inc. Announces Fourth Quarter 2024 Results

      Reports Quarterly Revenue of $298.4 Million, Reflecting 10.6% GrowthGenerated $52.2 Million of Quarterly Operating Cash FlowIssues Financial Guidance for 2025, Reflecting Tenth Consecutive Year of Revenue Growth NEW YORK, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY) ("Progyny" or the "Company"), a transformative fertility, family building and women's health benefits solution, today announced its financial results for the three- and twelve-month periods ended December 31, 2024 ("the fourth quarter of 2024" and "the full year", respectively) as compared to the three- and twelve-month periods ended December 31, 2023 ("the fourth quarter of 2023" and "the prior year period",

      2/27/25 4:01:22 PM ET
      $PGNY
      Misc Health and Biotechnology Services
      Health Care

    $PGNY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Executive Chairman Schlanger David J bought $2,202,330 worth of shares (150,000 units at $14.68), increasing direct ownership by 192% to 228,269 units (SEC Form 4)

      4 - Progyny, Inc. (0001551306) (Issuer)

      12/26/24 5:35:03 PM ET
      $PGNY
      Misc Health and Biotechnology Services
      Health Care
    • CHIEF EXECUTIVE OFFICER Anevski Peter bought $3,034,084 worth of shares (209,500 units at $14.48), increasing direct ownership by 90% to 441,463 units (SEC Form 4)

      4 - Progyny, Inc. (0001551306) (Issuer)

      12/26/24 5:31:32 PM ET
      $PGNY
      Misc Health and Biotechnology Services
      Health Care

    $PGNY
    Leadership Updates

    Live Leadership Updates

    See more

    $PGNY
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Progyny Names Healthcare Veterans Melissa Cummings as Chief Operating Officer and Geoffrey Clapp as Chief Product Officer

      NEW YORK, April 17, 2025 (GLOBE NEWSWIRE) -- Progyny (NASDAQ:PGNY), a global leader in women's health and family building, today announced the appointments of Melissa Cummings as the company's first Chief Operating Officer (COO) and Geoffrey Clapp as its first Chief Product Officer (CPO). The additions to the executive leadership team will extend Progyny's ability to further drive operational excellence, advance innovation in product design and member experience, and continue to address care gaps and unmet needs across the spectrum of family building and women's health – from preconception to fertility and menopause. "Progyny has established itself at the forefront of building and del

      4/17/25 9:36:59 AM ET
      $PGNY
      Misc Health and Biotechnology Services
      Health Care
    • Bruker Appoints Laura Francis to its Board of Directors

      Bruker Corporation (NASDAQ:BRKR) today announced that its Board of Directors has appointed Laura Francis to serve on its board as an independent director, effective as of February 18, 2025. Ms. Francis is also expected to join Bruker's Audit Committee as a financial expert after Bruker's annual shareholder meeting at the end of May 2025. Laura Francis is the Chief Executive Officer and a Board Member of SI-BONE, Inc. (NASDAQ:SIBN), a medical device company solving musculoskeletal disorders of the sacropelvic anatomy. She was previously the Chief Financial Officer and Chief Operating Officer of the company. Prior to joining SI-BONE, Ms. Francis held other executive and leadership roles with

      2/21/25 8:00:00 AM ET
      $BRKR
      $PGNY
      $SIBN
      $SWAV
      Biotechnology: Laboratory Analytical Instruments
      Industrials
      Misc Health and Biotechnology Services
      Health Care
    • Progyny, Inc. Enhances Suite of Services with Acquisition of BenefitBump

      NEW YORK, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY), a transformative fertility, family building, and women's health benefits solution, today announced the acquisition of BenefitBump, a comprehensive parental leave benefits navigation program for new and growing families. This addition enhances Progyny's fertility and family building offering, extending the company's ability to further serve the needs of families on their journey from pregnancy to early childhood and beyond. With 90% of parents seeking greater support to manage responsibilities at work and home, Progyny's enhanced suite of solutions aims to reduce member stress, improve recruitment, return-to-work and

      1/28/25 8:44:00 AM ET
      $PGNY
      Misc Health and Biotechnology Services
      Health Care
    • Progyny, Inc. Announces First Quarter 2025 Results

      Reports Record Revenue of $324.0 Million, Reflecting 16.5% GrowthRaises Full Year Guidance Due to Strong Start to the YearEarly Selling Season Activity Reflects Ongoing Demand in Women's Health and Family Building Solutions NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY) ("Progyny" or the "Company"), a global leader in women's health and family building solutions, today announced its financial results for the three-month period ended March 31, 2025 ("the first quarter of 2025") as compared to the three-month period ended March 31, 2024 ("the first quarter of 2024" or "the prior year period"). "We're pleased with the strong start to the year, highlighted by both our

      5/8/25 4:14:54 PM ET
      $PGNY
      Misc Health and Biotechnology Services
      Health Care
    • Progyny, Inc. Announces Details for Its First Quarter 2025 Results Report

      NEW YORK, April 24, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY), a global leader in women's health and family building, will report its financial results for the quarterly period ended March 31, 2025, after the close of the market on Thursday, May 8, 2025. The company will host a conference call at 4:45 p.m. Eastern Time (1:45 p.m. Pacific Time) and issue a press release regarding its financial results prior to the start of the call. Interested participants in the United States may access the conference call by dialing 1.866.825.7331 and using the passcode 265484. International participants may access the call by dialing 1.973.413.6106 and using the same passcode. An audio repl

      4/24/25 2:49:33 PM ET
      $PGNY
      Misc Health and Biotechnology Services
      Health Care
    • Progyny Names Healthcare Veterans Melissa Cummings as Chief Operating Officer and Geoffrey Clapp as Chief Product Officer

      NEW YORK, April 17, 2025 (GLOBE NEWSWIRE) -- Progyny (NASDAQ:PGNY), a global leader in women's health and family building, today announced the appointments of Melissa Cummings as the company's first Chief Operating Officer (COO) and Geoffrey Clapp as its first Chief Product Officer (CPO). The additions to the executive leadership team will extend Progyny's ability to further drive operational excellence, advance innovation in product design and member experience, and continue to address care gaps and unmet needs across the spectrum of family building and women's health – from preconception to fertility and menopause. "Progyny has established itself at the forefront of building and del

      4/17/25 9:36:59 AM ET
      $PGNY
      Misc Health and Biotechnology Services
      Health Care

    $PGNY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Progyny Inc.

      SC 13G/A - Progyny, Inc. (0001551306) (Subject)

      12/6/24 10:11:35 AM ET
      $PGNY
      Misc Health and Biotechnology Services
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Progyny Inc.

      SC 13G/A - Progyny, Inc. (0001551306) (Subject)

      11/14/24 4:31:23 PM ET
      $PGNY
      Misc Health and Biotechnology Services
      Health Care
    • SEC Form SC 13G/A filed by Progyny Inc. (Amendment)

      SC 13G/A - Progyny, Inc. (0001551306) (Subject)

      2/14/24 6:29:49 AM ET
      $PGNY
      Misc Health and Biotechnology Services
      Health Care

    $PGNY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Progyny downgraded by Analyst with a new price target

      Analyst downgraded Progyny from Overweight to Neutral and set a new price target of $17.00

      12/2/24 10:07:08 AM ET
      $PGNY
      Misc Health and Biotechnology Services
      Health Care
    • Progyny downgraded by Truist with a new price target

      Truist downgraded Progyny from Buy to Hold and set a new price target of $19.00 from $26.00 previously

      11/13/24 8:20:07 AM ET
      $PGNY
      Misc Health and Biotechnology Services
      Health Care
    • Progyny downgraded by JMP Securities

      JMP Securities downgraded Progyny from Mkt Outperform to Mkt Perform

      9/19/24 7:51:03 AM ET
      $PGNY
      Misc Health and Biotechnology Services
      Health Care